Genetic intratumoural heterogeneity is a natural consequence of imperfect DNA replication.
Any two randomly selected cells, whether normal or cancerous, are therefore genetically …

Despite the development of drugs inhibiting the oncogenic proteins that cancer cells are
dependent on, attempts to match targeted therapies to the genetic makeup of individual …

Tumour heterogeneity poses a substantial problem for the clinical management of cancer.
Somatic evolution of the cancer genome results in genetically distinct subclones in the …

Theories of cancer biology have long held that the metastatic process originates with rare
cells within the primary tumor. A new study using expression array analysis has identified a …

Targeted therapies provide an exciting new approach to combat human cancer. The
immediate effect is a dramatic reduction in disease burden, but in most cases, the tumor …

Intratumoral genetic heterogeneity of driver somatic mutations is present in a variety of tumor
types, yet the extent of heterogeneity is variable. We propose that this variation is a reflection …

Metastases are responsible for the majority of cancer-related deaths. Although genomic
heterogeneity within primary tumors is associated with relapse, heterogeneity among …

Metastasis is the primary cause of cancer-related deaths, but the natural history, clonal
evolution and impact of treatment are poorly understood. We analyzed whole-exome …

Mutations in oncogenes and tumor suppressor genes are responsible for tumorigenesis and
represent favored therapeutic targets in oncology. We exploited homologous recombination …

The authors review and discuss the implications of genomic analyses documenting the
diversity of tumors, both among patients and within individual tumors. Genetic diversity …